Physician profile
Marina Basina
NPI 1023196805
$18,401.19
in general payments reported to CMS, 2019-2025
23 companies · $4,051 in 2025
The $4,051 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $5,252 · 2021: $1,622 · 2022: $4,116 · 2023: $2,170 · 2024: $121 · 2025: $4,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,229 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,002 · Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,228.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,002.23 |
| Food and Beverage | $1,111.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $4,555.73 | 2019-2020 | |
| Eli Lilly and Company | $4,000.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $3,480.30 | 2025 | |
| Renalytix Ai, INC. | $2,002.23 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Ascensia Diabetes Care US INC. | $1,500.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $688.00 | 2020 | |
| Novo Nordisk INC | $341.18 | 2019-2021 | |
| Dexcom, INC. | $275.24 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Corcept Therapeutics | $234.62 | 2019-2025 | Korlym |
| Lilly USA, LLC | $198.01 | 2019-2022 | |
| Medtronic, INC. | $147.45 | 2025 | Minimed 780g |
| Sequel Med Tech, LLC | $144.73 | 2025 | Twiist |
| Insulet Corporation | $143.28 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $140.22 | 2019 | |
| Amgen INC. | $121.83 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $121.42 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $102.26 | 2019 | |
| Allergan, INC. | $92.71 | 2019 | |
| Senseonics, Incorporated | $51.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $31.94 | 2023 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $14.86 | 2019 | |
| Viiv Healthcare Company | $14.18 | 2023 | Dovato |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Basina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.